PRIMARY (CP.A.B.C.D); PRIMARY (UP.A.B.C.D); PRIMARY-Z (PS.A.B.C.D); PRIMARY-Z (PSS.A.B.C.D); PRIMARY-Z (PSD.A.B.C.D); PRIMARY-O (OR.A.B.C.D); PRIMARY-O (ORS.A.B.C.D); PRIMARY-O (ORD.A.B.C.D)
Cusmedi Co., Ltd. · Decision date Nov 6, 2026
What did the FDA decide?
FDA records K254222 as a 510(k) premarket notification, with a decision dated Nov 6, 2026. The decision code SESE records a finding of substantial equivalence. This is a 510(k) clearance.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- Neurology
- Decision date
- Nov 6, 2026
Regulatory record facts
- Identifier
- K254222
- Regulatory pathway
- 510(k) premarket notification
- Applicant
- Cusmedi Co., Ltd.
- Product code
- GXN
- Decision code
- SESE
- Decision date
- Nov 6, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Plate, Cranioplasty, Preformed, Non-Alterable.
- Applicant
- Cusmedi Co., Ltd.
- Product code
- GXN
- FDA device class
- 2
FDA decision timeline
K254222 received
Application receipt date recorded by FDA.
K254222 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
No additional submissions with a verified PMA or product-code relationship are linked here.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Cusmedi Co., Ltd.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Suwon-Si
Sources and methodology
- Original FDA record: K254222
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records